Drug Trial Radar · NCT07914673
Age-Associated Differences in Germinal Center Responses to Influenza and Rabies Vaccination in Humans
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 25, 2026
Primary completion
Feb 1, 2027
Study completion Sep 25, 2027
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID); Bill and Melinda Gates Foundation
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to better understand how the immune system responds to vaccination against influenza and rabies. Researchers want to study how immune responses develop and change over time in the blood and in the lymph nodes that drain the vaccination site, following vaccination with two vaccines licensed by the U.S. Food and Drug Administration (FDA): the seasonal trivalent influenza vaccine (TIV) and the rabies vaccine (RabAvert). By studying these samples, researchers hope to learn how the body produces high-quality, long-lasting antibody and memory immune responses after vaccination. The study will also compare immune responses in younger adults to immune responses in older adults, because prior research suggests that the immune system's ability to respond to vaccination weakens with age.
Conditions
- Healthy Adult Participants
- Age 65 and Older
- Age 18 to 40
- Immunology
Interventions
Trivalent inactivated influenza vaccineBiological
Standard, seasonal flu vaccines
RabAvertBiological
Rabies vaccine for pre-exposure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rabies-specific antibody titers at day 29 compared to pre-vaccination baseline.Time frame: From vaccination day 1 to day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.